STANDARD BIOTOOLS INC.

# Signal Note: Casdin Capital Initiates $113.6M Position in Standard Biotools (LAB) Casdin's entry into LAB signals confidence in the company's microfluidics and single-cell analysis platform, which serves drug discovery and cell therapy workflows—critical infrastructure for genomics-driven R&D. The $113.6M stake (representing a substantial position) suggests conviction in LAB's TAM expansion as biotech increasingly adopts high-throughput phenotyping and functional genomics tools. Near-term catalysts to monitor include customer adoption metrics, gross margin trajectory, and any partnerships with major pharma conducting target validation.